What is it about?
Technical advances in the analysis of biological markers have generated a plethora of promising candidates for the early detection of cancer. However, only a small proportion of these markers have been successfully validated as predictive, clinically useful, or effective in subsequent studies. Methodological issues remain a major challenge in molecular epidemiological research on diagnostic biomarkers. Despite the availability of guidelines for biomarker studies, substantial improvements in study planning and execution are still needed. This article discusses potential sources of bias related to study design, specimen collection and handling, and statistical analysis, thereby highlighting common pitfalls in biomarker research. In addition, it addresses the legal, ethical, and technical aspects of specimen storage and management, providing guidance on epidemiological standards and best practices in biomarker research.
Featured Image
Photo by Guille B on Unsplash
Why is it important?
So far, only a few biological markers have been shown to be clinically useful through validation studies. Moreover, many biomarker studies do not meet established epidemiological standards. The article discusses several key pitfalls in biomarker research.
Perspectives
Biomarker studies, especially those aimed at the early detection of disease, continue to pose substantial methodological challenges. Large prospective cohort studies usually require extensive follow-up periods, considerable resources, and long-term commitment. While recent advances in artificial intelligence have opened new avenues for identifying promising biomarker candidates, most still require rigorous validation before they can be translated into clinical practice. Preparing this overview of epidemiological standards and common pitfalls in biomarker research has been both challenging and rewarding. We hope that the article will help raise awareness of methodological issues and provide practical guidance for researchers seeking to conduct high-quality biomarker studies.
Thomas Behrens
Institute for Prevention and Occupational Medicine of the German Accident Insurance, Institute of the Ruhr-University Bochum
Read the Original
This page is a summary of: A practical guide to epidemiological practice and standards in the identification and validation of diagnostic markers using a bladder cancer example, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, January 2014, Elsevier,
DOI: 10.1016/j.bbapap.2013.07.018.
You can read the full text:
Contributors
The following have contributed to this page
